Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB107 in Advanced Solid Tumors With Bone Metastases
NCT07087197Phase 1Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Aug 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SKB107 in solid tumor and prostate cancer (PCa) (2 arms), sponsored by Kelun-Biotech. Primary endpoint: Adverse Events up to 3 years. Started Aug 2025; status: recruiting.
02
Drugs
SKB107
03
Conditions
solid tumorprostate cancer (PCa)
Beyond the preview
Go deeper on NCT07087197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07087197.